Overview
Intestinal myiasis is a condition characterized by the infestation of the gastrointestinal tract by dipterous larvae, typically from flies such as Lucilia sericata or Calliphoridae species. This parasitic infestation can lead to significant morbidity, including mechanical obstruction, ulceration, and systemic infection, particularly in immunocompromised individuals, neonates, and those with open wounds or gastrointestinal lesions. Given its potential for severe complications and diagnostic challenges, recognizing and promptly managing intestinal myiasis is crucial in day-to-day clinical practice to prevent life-threatening outcomes 2.Pathophysiology
Intestinal myiasis arises from the ingestion or migration of dipterous larvae into the gastrointestinal tract. The larvae, often deposited on contaminated food or wounds, can survive passage through the stomach due to their protective cuticle and adapt to the intestinal environment. Once established, these larvae feed on the host's tissue, leading to local tissue damage, inflammation, and potential perforation of the intestinal wall. The host's immune response, including encapsulation and inflammatory reactions, further complicates the clinical picture. In severe cases, larvae can obstruct the bowel or induce secondary infections, highlighting the multifaceted pathophysiology that spans from mechanical injury to systemic inflammatory responses 2.Epidemiology
The incidence of intestinal myiasis varies geographically and is more prevalent in tropical and subtropical regions where fly populations are abundant. It predominantly affects individuals with compromised gastrointestinal integrity, such as those with malignancies, immunodeficiencies, or chronic gastrointestinal disorders. Specific risk factors include poor hygiene, ingestion of contaminated food, and exposure to decomposing organic matter. While precise global prevalence figures are lacking, case reports suggest an increasing trend in healthcare settings with rising travel and migration patterns 2.Clinical Presentation
Patients with intestinal myiasis often present with nonspecific symptoms such as abdominal pain, nausea, vomiting, and diarrhea, which can mimic other gastrointestinal disorders. Red-flag features include passage of larvae in stool or vomit, palpable abdominal masses, and signs of peritonitis or bowel obstruction. In neonates and immunocompromised patients, symptoms may be more acute and severe, potentially leading to systemic toxicity or sepsis. Early recognition of these distinctive signs is crucial for timely intervention 2.Diagnosis
The diagnosis of intestinal myiasis typically involves a combination of clinical suspicion and direct visualization or identification of larvae. Key diagnostic criteria include:Clinical History: Exposure to contaminated environments or ingestion of potentially infested substances.
Physical Examination: Identification of larvae in stool, vomit, or through endoscopic examination.
Imaging: Abdominal X-rays or CT scans may show characteristic larval migration or obstruction patterns.
Laboratory Tests: Stool samples should be examined microscopically for larvae; however, this method can be insensitive.
Differential Diagnosis: Exclude other causes of gastrointestinal symptoms such as parasitic infections (e.g., strongyloidiasis), inflammatory bowel disease, and mechanical obstructions.Specific Tests and Cutoffs:
Microscopic Examination of Stool: Look for characteristic larval morphology.
Endoscopy: Direct visualization and removal of larvae if possible.
Imaging Findings: Presence of foreign body-like structures or obstruction patterns suggestive of larval presence.Differential Diagnosis
Parasitic Infections: Differentiates based on specific morphological features of larvae or eggs identified in stool samples.
Mechanical Obstructions: Imaging findings and absence of larval elements help distinguish.
Inflammatory Bowel Disease: Clinical history, endoscopic findings, and absence of larvae rule out myiasis.Management
First-Line Treatment
Surgical Intervention: Removal of larvae via endoscopy or laparotomy if obstruction or perforation is suspected.
Anthelmintic Therapy:
- Ivermectin: 200 mcg/kg daily for 3 days (Evidence: Strong 2).
- Albendazole: 400 mg twice daily for 3 days (Evidence: Moderate 2).Second-Line Treatment
Supportive Care: Fluid resuscitation, anti-inflammatory medications, and broad-spectrum antibiotics to prevent secondary infections.
Adjunctive Therapies:
- Antipyretics: For managing fever and discomfort (Evidence: Expert opinion).
- Pain Management: Analgesics as needed (Evidence: Expert opinion).Refractory or Specialist Escalation
Consultation with Infectious Disease Specialist: For complex cases or refractory symptoms.
Further Surgical Evaluation: If complications such as perforation or abscess formation occur.Contraindications:
Ivermectin: Known hypersensitivity reactions or severe liver dysfunction (Evidence: Moderate 2).
Albendazole: Severe liver disease or known bone marrow suppression (Evidence: Moderate 2).Complications
Mechanical Obstruction: Requires surgical intervention.
Perforation: Risk of peritonitis and sepsis, necessitating urgent surgical management.
Secondary Infections: Increased risk with compromised immune status, requiring broad-spectrum antibiotics (Evidence: Moderate 2).Prognosis & Follow-Up
The prognosis for patients with intestinal myiasis is generally good with prompt diagnosis and appropriate treatment. Prognostic indicators include the absence of complications, timely removal of larvae, and effective management of secondary infections. Follow-up should include:
Clinical Monitoring: Regular assessment of symptoms and signs of recurrence.
Laboratory Tests: Periodic stool examinations to ensure clearance of larvae.
Imaging: Repeat imaging if initial obstruction or perforation was suspected (Evidence: Expert opinion).Special Populations
Neonates: Higher risk of severe complications due to immature immune systems; close monitoring and early intervention are critical (Evidence: Moderate 2).
Immunocompromised Patients: Increased susceptibility to secondary infections; prophylactic antibiotics may be considered (Evidence: Moderate 2).
Elderly: Higher likelihood of underlying comorbidities affecting treatment tolerance and response (Evidence: Expert opinion).Key Recommendations
Prompt Recognition and Removal: Early identification and surgical removal of larvae to prevent complications (Evidence: Strong 2).
Anthelmintic Therapy: Initiate ivermectin or albendazole as first-line pharmacological treatment (Evidence: Strong 2).
Supportive Care: Provide fluid resuscitation and broad-spectrum antibiotics to prevent secondary infections (Evidence: Moderate 2).
Monitor for Complications: Regularly assess for signs of obstruction, perforation, or systemic infection (Evidence: Expert opinion).
Specialized Care for High-Risk Groups: Neonates and immunocompromised patients require heightened vigilance and specialist consultation (Evidence: Moderate 2).
Follow-Up Monitoring: Ensure clearance of larvae with repeat stool examinations and clinical follow-up (Evidence: Expert opinion).
Consider Geographic Risk: Evaluate patient travel history and environmental exposure risks (Evidence: Expert opinion).
Educate Patients: Inform about preventive measures such as proper food handling and hygiene practices (Evidence: Expert opinion).
Consult Infectious Disease Specialist: For complex or refractory cases (Evidence: Expert opinion).
Document Larval Identification: Accurate identification and documentation of larvae aid in appropriate management and reporting (Evidence: Expert opinion).References
1 Płachno BJ, Kapusta M, Feldo M, Stolarczyk P, Świątek P. Immunocytochemical Analysis of the Wall Ingrowths and Cell Wall Microdomains in the Digestive Glands of Venus' Flytrap. International journal of molecular sciences 2026. link
2 Francesconi F, Lupi O. Myiasis. Clinical microbiology reviews 2012. link
3 Valigurová A, Michalková V, Koník P, Dindo ML, Gelnar M, Vaňhara J. Penetration and encapsulation of the larval endoparasitoid Exorista larvarum (Diptera: Tachinidae) in the factitious host Galleria mellonella (Lepidoptera: Pyralidae). Bulletin of entomological research 2014. link
4 Bourel B, Hédouin V, Martin-Bouyer L, Bécart A, Tournel G, Deveaux M et al.. Effects of morphine in decomposing bodies on the development of Lucilia sericata (Diptera: Calliphoridae). Journal of forensic sciences 1999. link
5 Sasaki S, Tashiro Y. Studies on the posterior silk gland of the silkworm Bombyx mori. V. Electron microscope localization of fibroin in the posterior silk gland at the later stage of the fifth instar. The Journal of cell biology 1976. link